Randomized, open-label, comparative parallel group study to assess efficacy and safety on flexible dosages of OROS hydromorphone once-daily compared to sustained-release oxycodone twice daily in subjects with chronic non-malignant pain requiring continuous opioid therapy.

Trial Profile

Randomized, open-label, comparative parallel group study to assess efficacy and safety on flexible dosages of OROS hydromorphone once-daily compared to sustained-release oxycodone twice daily in subjects with chronic non-malignant pain requiring continuous opioid therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Hydromorphone (Primary) ; Oxycodone (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 14 Jul 2009 Actual patient number (504) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by clinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top